Padcev plus Keytruda confirmed promising scientific exercise in UTUC lesions, with a 35% ORR in measurable lesions and an 87.5% illness management charge in major tumors.
Amongst sufferers with higher tract urothelial carcinoma (UTUC) lesions, the mix of Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) resulted in promising scientific exercise, research outcomes have proven.
Outcomes from a small retrospective evaluation had been shared in a poster on the 2025 ASCO Genitourinary Cancers Symposium.
The research, performed by a group of researchers from the Johns Hopkins Departments of Medical Oncology and Urology, confirmed that in major lesions for 16 sufferers handled with Padcev alone or Padcev plus Keytruda, the general response charge (ORR) was 25% (4 sufferers), consisting of all partial responses. Main lesions for an extra 10 sufferers confirmed steady illness, for a illness management charge of 87.5% (14 sufferers). Two sufferers had progressive illness.
Amongst all sufferers with measurable goal lesions at baseline (20 sufferers) the ORR was 35% (seven sufferers), consisting of all partial responses. An extra seven sufferers had steady illness for a illness management charge of 70% (14 sufferers). Six sufferers had progressive illness.
Glossary:
Total response charge: Sufferers in a scientific trial who responded partially or fully to therapy.
Examine Design and Rationale
In describing the rationale for his or her retrospective research, the authors defined that sufferers with UTUC are sometimes ineligible for normal perioperative care with cisplatin because of renal dysfunction associated to illness and surgical procedure. They added that, “Given the unprecedented exercise of [Padcev] plus [Keytruda] [previously demonstrated] in superior urothelial carcinoma, and security in impaired renal perform, the evaluation of this mixture in earlier illness settings for sufferers with UTUC is an pressing want.”
For his or her evaluation, the researchers included sufferers with intact major UTUC tumors who had acquired single-agent Padcev or Padcev plus Keytruda at Johns Hopkins. They collected baseline affected person traits by means of chart evaluation. The research parameters outlined major tumor as any lesion positioned within the ureter and/or renal pelvis.
The researchers recognized 50 sufferers with UTUC handled with Padcev alone or Padcev plus Keytruda at Johns Hopkins between December 2017 and June 2024. Of those sufferers, 22 had intact major tumors and had been thus included within the retrospective evaluation. Baseline traits confirmed that the median affected person age was 72 years, 59% (13 sufferers) had been male, and 77.3% (17 sufferers) had been White. Tumor evaluation confirmed that 86.4% of sufferers (19 sufferers) had pure urothelial histology and 81.8% of sufferers (18 sufferers) had visceral metastases.
Of the 22 sufferers with intact major tumors, 59.1% (13 sufferers) acquired Padcev alone and 40.9% (9 sufferers) acquired Padcev plus Keytruda. Three sufferers started their Padcev routine at a diminished dose. The median variety of Padcev cycles acquired was 4. The median therapy period was 3.3 months.
The mix of Padcev and Keytruda is at the moment accepted by the FDA for the therapy of grownup sufferers with regionally superior or metastatic urothelial most cancers.
Of their conclusion, the researchers wrote, “Bigger potential research are wanted to evaluate the efficacy of this promising routine within the perioperative setting for sufferers with this uncommon and aggressive illness.”
Reference:
Main tumor response to enfortumab vedotin with/with out pembrolizumab in sufferers with higher tract urothelial most cancers, by Dr. Evangelia Vlachou, et al., Journal of Scientific Oncology.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
